SLC7A5 and irritable bowel syndrome: Namely, the expression of SLC7A5 showed a significant, and biologically relevant (i.e., below the 0.5-fold mark, typically considered as cutoff for biologically relevant downregulation (vs above 2-fold increase is typically considered a biologically relevant upregulation)), decrease in all conditions compared to G-Krebs (HC-CON: -9.1 ± 2.9, p = 0.0052; HC-BUT: -8.9 ± 2.9, p = 0.0063; IBS-CON: -8.7 ± 2.7, p = 0.0040; IBS-BUT: -8.4 ± 2.7, p = 0.0053; HC-FERFIB: -9.5 ± 2.7, p = 0.0022; all F(7, 19) = 3.1) (Fig. 2).